SUCRA rankings confirmed the superior probability of benefits for rasagiline-based interventions across multiple QoL dimensions.<h4>Conclusion</h4>This network meta-analysis provides evidence that MAO-B inhibitors, particularly rasagiline and safinamide, may offer broader QoL benefits in patients with PD, especially in NMS such as emotional well-being. Here, MAOB is linked to Parkinson disease.